1-5 of 5
Prasanna Kumar, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clonal Expansion of Mutant p53 Clones By MDM2 Inhibition in Acute Myeloid Leukemias

Yuki Nishida, MDPhD, Rafael Heinz Montoya, BS, Kiyomi Morita, MDPhD, Tomoyuki Tanaka, MDPhD, Feng Wang, PhD, Koichi Takahashi, MD PhD, Jo Ishizawa, MDPhD, Prasanna Kumar, PhD, Parul Patel, PhD, Cedric E. Dos Santos, PhD, Courtney D. DiNardo, MD MSCE, Michael Andreeff, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–28.
https://doi.org/10.1182/blood-2020-142794
Published: 2020
Journal Articles

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Courtney D. DiNardo, MDMSc, Rebecca Olin, MDMS, Jo Ishizawa, MD PhD, Hiroyuki Sumi, PhD, Jingdong Xie, PhD, Kazunobu Kato, MD PhD, Prasanna Kumar, PhD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3932.
https://doi.org/10.1182/blood-2019-122241
Published: 2019
Journal Articles

A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Naval G. Daver, MD, Weiguo Zhang, MD PhD, Richard Graydon, MD PhD, Vikas K Dawra, MBA, PhD, Jingdong Xie, PhD, Prasanna Kumar, PhD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1389.
https://doi.org/10.1182/blood-2019-122585
Published: 2019
Journal Articles

Synergistic Anti-Leukemic Activity with Combination of FLT3 Inhibitor Quizartinib and MDM2 Inhibitor Milademetan in FLT3-ITD Mutant/p53 Wild-Type Acute Myeloid Leukemia Models

Michael Andreeff, MD PhD, Weiguo Zhang, MD PhD, Prasanna Kumar, PhD, Oleg Zernovak, MD, Naval G. Daver, MD, Takeshi Isoyama, PhD, Kouichi Iwanaga, D.V.M, PhD, Noriko Togashi, Takahiko Seki, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2720.
https://doi.org/10.1182/blood-2018-99-115183
Published: 2018
Journal Articles

Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies - Preliminary Results

Courtney D DiNardo, MD, Joseph Rosenthal, MD MS, Michael Andreeff, MD PhD, Oleg Zernovak, MD, Prasanna Kumar, PhD, Roohi Gajee, PhD, Shuquan Chen, PhD, Michael Rosen, PhD, Saeheum Song, PhD, Jarema Kochan, PhD, Tharin Limsakun, PhD, Rebecca Olin, MD
Journal: Blood
Blood (2016) 128 (22): 593.
https://doi.org/10.1182/blood.V128.22.593.593
Published: 2016